Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Biotronik reports positive six-month results from BIOLUX P-II study

Biotronik has reported the positive six-month results from the BIOLUX P-II study, a randomized, controlled multicenter study designed to investigate the performance of the Passeo-18 Lux DRB compared to an uncoated Passeo-18 PTA catheter in the treatment of lesions in the infrapopliteal (below-knee) segment.

Scientists presented the findings at the Leipzig Interventional Course 2014 conference.

The primary clinical endpoint was major adverse event rate or MAE, a composite of all cause death, major amputation of target extremity, Target Lesion Revascularization (TLR), Target Vessel Revascularization (TVR), and target lesion thrombosis.

Despite the high-risk patient population, the 30-day MAE rate was 0.0% in the DRB group compared to 8.3% in the PTA group.

Six-month primary efficacy endpoint documented a target lesion primary patency rate of 84.3% in the DRB group versus 75.9% in the PTA group.

Passeo-18 Lux is a novel treatment for de novo and restenotic femoropopliteal lesions.

The device is based on the proven Passeo-18 PTA catheter, coated with a matrix of antiproliferative paclitaxel and a biocompatible excipient — enabling an optimal drug transfer to target lesion tissue.

In addition, Passeo-18 Lux features a unique, user-friendly insertion aid, which protects the user and balloon coating from contact and damage.

Biotronik Vascular Intervention vice president of marketing Dr. Alexander Uhl said the results of BIOLUX P-I and P-II confirm Passeo-18 Lux DRB as a safe and effective therapy option for both above- and below-knee arterial disease.

"Our significant investments in developing outstanding peripheral vascular devices, supported by clinical evidence, improve patients’ quality of life," Dr Uhl added.